A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 1157
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : VKA
Long Form : vitamin K antagonists
No. Year Title Co-occurring Abbreviation
2020 A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study. BMI, INR
2020 A review of guidelines on anticoagulation reversal across different clinical scenarios - Is there a general consensus? 4F-PCCs, DOAC
2020 Activated Clotting Time Monitoring during Atrial Fibrillation Catheter Ablation: Does the Anticoagulant Matter? ACT, AF, DOACs, UFH
2020 Acute Ischemic Stroke Outcome and Preceding Anticoagulation: Direct Oral Anticoagulants Versus Vitamin K Antagonists. AIS, DOAC, OAC
2020 All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease. AF, ARD, ARD, VHD
2020 Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients. AF, NOACs
2020 Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. AF, DOAC, ICH, VTE
2020 Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry. APD, DOAC, NVAF, OAT
2020 Antithrombotic strategies in patients needing oral anticoagulation undergoing percutaneous coronary intervention: A network meta-analysis. ACS, CI, DAT, ICH, OAT, PCI, RCTs, ST, TAT, TIMI
10  2020 Antithrombotic Strategies in Patients with Atrial Fibrillation Following Percutaneous Coronary Intervention: A Systemic Review and Network Meta-Analysis of Randomized Controlled Trials. AF, CrI, NOACs, OR, PCI, TIMI
11  2020 Antithrombotic treatment and major adverse cardiac events after bleeding in patients with myocardial infarction: a retrospective analysis of nationwide registry data. MACE, MI
12  2020 Benefit of dual antithrombotic therapy with direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials. ACS, CI, DAT, DOAC, MACE, OR, TAT
13  2020 Bleeding and thrombotic outcomes associated with postoperative use of direct oral anticoagulants after open peripheral artery bypass procedures. DOACs
14  2020 Blood Pressure and Anticoagulation Reversal Management during Off-Hours in Oral Anticoagulation-Associated Intracerebral Hemorrhage. BP, INR, mRS, NOAC, OAC-ICH, PSM
15  2020 Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study. CUA
16  2020 Changes in anticoagulant prescription in Dutch patients with recent-onset atrial fibrillation: observations from the GARFIELD-AF registry. AF, NOAC
17  2020 Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population-based propensity-weighted cohort study. CES, HR, NOAC, NVAF
18  2020 Coagulation and heparin requirements during ablation in patients under oral anticoagulant drugs. ACT, DOAC
19  2020 Comparative Efficacy and Safety of Sulodexide and Other Extended Anticoagulation Treatments for Prevention of Recurrent Venous Thromboembolism: A Bayesian Network Meta-analysis. CRNMB, DOACs, MB, MI, NMA, PE, R-DVT, RCTs, VTE
20  2020 Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study. AF, CI, DOACs, HR
21  2020 Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonist in cerebral venous thrombosis. CVT, DOAC
22  2020 Comparison of Traumatic Intracranial Hemorrhage Expansion and Outcomes Among Patients on Direct Oral Anticoagulants Versus Vitamin k Antagonists. DOACs, GOS, tICH
23  2020 Death rates and causes in anticoagulated atrial fibrillation patients: a population-based study. CI, DOACs
24  2020 Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography. CAT, MB, VTE
25  2020 Diagnosis and management of congenital thrombophilia in the era of direct oral anticoagulants. DOAC
26  2020 Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. DOAC, LV
27  2020 Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study. DOAC, NVAF
28  2020 Direct-acting Anticoagulants in Chronic Coronary Syndromes. CCS, DAPT, DOACs, NVAF
29  2020 Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project. AMS, INR, PSC, TTR
30  2020 Dual anti-thrombotic treatment with direct anticoagulants improves clinical outcomes in patients with Atrial Fibrillation with ACS or undergoing PCI. A systematic review and meta-analysis. DAT, DOAC, TAT
31  2020 Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. ACS, AF, CCS, CI, HR, PCI, Pint
32  2020 Edoxaban versus warfarin in vitamin K antagonist experienced and naive patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial. CI, enox-warf, ENSURE-AF, OR
33  2020 Effect of antithrombotic drugs on bone health. ASA, LMWH, NOACs, UFH
34  2020 Effect of multidose drug dispensing on the time in therapeutic range in patients using vitamin-K antagonists: A randomized controlled trial. MDD, TTR
35  2020 Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study. INR, TTR
36  2020 Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial. AF, hs-CRP, hs-IL-6, TAT
37  2020 Efficacy and safety outcomes in novel oral anticoagulants versus vitamin-K antagonist on post-TAVI patients: a meta-analysis. NOACs, TAVI
38  2020 Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in patients with venous thromboembolism treated with vitamin K antagonists: Findings from the RIETE registry. RIETE, TTR, VTE
39  2020 Factors associated with silent cerebral events during atrial fibrillation ablation in patients on uninterrupted oral anticoagulation. ACT, AF, LAD, OAC, SCEs
40  2020 Frailty, Cognitive Impairment, and Anticoagulation Among Older Adults with Nonvalvular Atrial Fibrillation. CI, DOAC, NVAF, OAC, OR
41  2020 Heterogeneity in Preferences for Anti-coagulant Use in Atrial Fibrillation: A Latent Class Analysis. DOAC, LCA, MLA
42  2020 How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome. APS
43  2020 How I treat venous thromboembolism in pregnancy. CTPA, DOACs, DVT, LMWH, PE, VTE
44  2020 Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD-AF registry. AF, BE, NL, NOAC, TE
45  2020 Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation. NOAC
46  2020 Influence of oral anticoagulation on stroke severity and outcomes: A propensity score matching case-control study. DOAC, OAC
47  2020 Intracerebral hemorrhage outcomes in patients using direct oral anticoagulants versus vitamin K antagonists: a meta-analysis. DOAC, ICH, RR, WMDs
48  2020 Intracranial calcifications under vitamin K antagonists or direct oral anticoagulants: Results from the French VIKING study in older adults. DOA, FAB
49  2020 Ischemic Stroke and Transient Ischemic Attack Risk Following Vitamin K Antagonist Cessation in Newly Diagnosed Atrial Fibrillation: A Cohort Study. AF, TIAs
50  2020 Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation. AF, AIS, CIs, DOAC, HRs, IQR
51  2020 Joint Mexican position document on the treatment of atrial fibrillation. AF, AV
52  2020 Long-term vitamin-K antagonist use and coronary artery calcification. CAC, CT, CV, MPVs
53  2020 Low persistence to rivaroxaban or warfarin among patients with new venous thromboembolism at a safety net academic medical center. DOAC, VTE
54  2020 Management of thrombocytopenia in a patient with a mechanical mitral valve undergoing autologous hematopoietic stem cell transplantation: case report and review of literature. HSCT, INR
55  2020 Meta-analysis Comparing Direct Oral Anticoagulants Versus Vitamin K Antagonists After Transcatheter Aortic Valve Implantation. AF, CI, DOACs, OR, TAVI
56  2020 Meta-Analysis of Antithrombotic Strategies in Patients With Heart Failure With Reduced Ejection Fraction and Sinus Rhythm. CI, HFrEF, RR
57  2020 Meta-analysis of Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. AF, DAPT, DOAC, PCI
58  2020 Meta-analysis of the safety and efficacy of using minimally interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation. AF, CA, CI, MRI, NOAC, OR, SCI
59  2020 Minimally Interrupted Non-Vitamin K Antagonist Oral Anticoagulants vs. Bridging Therapy and Uninterrupted Vitamin K Antagonists During Atrial Fibrillation Ablation: A Retrospective Single-Center Study. AF, CCE, NOAC
60  2020 MRI characteristics in acute ischemic stroke patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists. AIS, DOAC, LVO
61  2020 MT in anticoagulated patients: Direct oral anticoagulants versus vitamin K antagonists. AIS, CI, DOA, MT, mTICI, OR
62  2020 NOAC-based dual therapy versus warfarin-based triple therapy after percutaneous coronary intervention or acute coronary syndrome in patients with atrial fibrillation: A systematic review and meta-analysis. ACS, CRNM, DT, ISTH, MACCE, NOAC, OR, PCI, RCTs, ST, TT
63  2020 Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study. AA, ACHD, NOACs, NOACs, QOL
64  2020 Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type. CRNM, DAPT, DAT, DAT, ISTH, MACE, MI, NOAC, PCI, RRR, SAPT, ST, TAT
65  2020 One-Year Course of Periprocedural Anticoagulation in Atrial Fibrillation Ablation: Results of a German Nationwide Survey. AF, EP, NOAC, OAC
66  2020 Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. AF, DAPT, MACE, NOAC, ORs, PCI, PRISMA, TIMI
67  2020 Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials. VTE
68  2020 Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study. ALI, NOAC, NVAF, OACs, PLD
69  2020 Outcome of older hip fracture patients on anticoagulation: a comparison of vitamin K-antagonists and Factor Xa inhibitors. FXa, OAC
70  2020 Outpatient Treatment of Low-Risk Pulmonary Embolism in the Era of Direct Oral Anticoagulants: A Systematic Review. DOAC, ED, NRTs, PE, RCTs, VTE
71  2020 Patient Knowledge about Oral Anticoagulation Therapy Assessed during an Intermediate Medication Review in Swiss Community Pharmacies. MR, NOAC, OAC, PMC
72  2020 Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study). AF, PACT-Q
73  2020 Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: clinical outcomes in a single centre cohort after long-term follow-up. AF, MHV, PSM, pt-ys, TTR, VTE
74  2020 Patients' satisfaction associated with portable coagulometers for warfarin monitoring: a cross-sectional study. DASS, INR, POC
75  2020 Patterns of oral anticoagulation use with cardioversion in clinical practice. AF, NOAC, TIA, TOE
76  2020 Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. AF, DOAC's
77  2020 Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2. 4F-PCC, FX, INR
78  2020 Prediction of significant bleeding during vitamin K antagonist treatment for venous thromboembolism in outpatients. CRNMB-H, VTE
79  2020 Prescription rates of cardiovascular and diabetes therapies prior to and during the COVID-19 lockdown in Germany. ACE, CCB
80  2020 Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism. CTEPH, ORs, PE, TTR
81  2020 Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN. AF, DOAC, QOL, TTR
82  2020 Quality of life, medication adherence and satisfaction with anticoagulant treatment (dabigatran vs vitamin K antagonists) according to thromboembolic risk. Data from the CAPANA study. NVAF
83  2020 Quantitative Volumetric Comparison of Direct Oral Anticoagulant and Vitamin K Antagonist Treatment for Pulmonary Thrombus Reduction During the Acute Phase in Symptomatic Patients. DOAC, PTE
84  2020 Rationale and design of a prospective multi-center randomized trial of EARLY treatment by rivaroxaban versus warfarin in ST-segment elevation MYOcardial infarction with Left Ventricular Thrombus (EARLY-MYO-LVT trial). DAPT, LVT, NOACs, STEMI
85  2020 Real-world adherence to oral anticoagulants in atrial fibrillation AF, NOAC, OAC
86  2020 Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study. AF, CI
87  2020 Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. ACS, AF, DATs, ISTH, MI, NOACs, OR, PCI, TAT
88  2020 Safety and effectiveness of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal following a fixed-dose strategy. APTT, INR, PCC
89  2020 Safety and efficacy of direct oral anticoagulants compared to Vitamin K antagonists postpercutaneous coronary interventions in patients with atrial fibrillation: A systematic review and meta-analysis. AF, CAD, CRNB, DOACs, ISTH, MACE, PCI, RCTs
90  2020 Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. DAPT, HR, NOAC, SAPT
91  2020 Severe Hemorrhage Associated With Oral Anticoagulants. DOAC, PCCs
92  2020 Short-term prognosis of breakthrough venous thromboembolism in anticoagulated patients. LMWH, VTE
93  2020 Similar outcomes between vitamin K and non-vitamin K antagonist oral anticoagulants associated intracerebral hemorrhage. ICH, mRS, NOAC
94  2020 Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. AGIMM, IWG-MRT, MPN
95  2020 Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns. DOACs, OR
96  2020 Switching from Warfarin to rivaroxaban induces sufficiency of vitamin K and reduction of arterial stiffness in patients with atrial fibrillation. baPWV, ucOC
97  2020 The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. AF, RCT, RHD
98  2020 The Risk / Benefit Tradeoff of Antithrombotic Therapy in Patients with Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights from AUGUSTUS. ACS, AF, PCI
99  2020 The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants. DOAC, DVT, PTS
100  2020 The Use of Novel Oral Anti-Coagulant's (NOAC) compared to Vitamin K Antagonists (Warfarin) in patients with Left Ventricular thrombus after Acute Myocardial Infarction (AMI). AMI, NOAC, PCI